Paper Review Records
全部论文审稿周期
24 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
185
天
CLDN6 defines a liver-metastatic CMS4 subgroup in colorectal cancer via CLDN6–SRC–FOXO1 signaling and epigenetic reprogramming
作者
Rui Li; Yaoyao Zhou; Qingwu Du; Wenxia Zhao; Shihui Cao; Bo Ni; Ziyun Liu; Chao Liu; Feng Liu; Jie Zhang; Yongjie Xie; Yamei Han; Chunnuan Wu展开收起
作者单位
1. Department of Biochemistry and Molecular Biology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, Tianjin, China; 2. Tianjin’s Clinical Research Center for Cancer, Tianjin, Tianjin, China; 3. Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, China; 4. Department of Laboratory, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, Tianjin, China; 5. Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Henan, Zhengzhou, China; 6. Institute of Cancer Research, Henan Academy of Innovations in Medical Science, Henan, Zhengzhou, China; 7. Department of Pharmacy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, Tianjin, China; 8. Pancreas Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, Tianjin, China; 9. State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin, Tianjin, China; 10. Tianjin Key Laboratory of Digestive Cancer, Tianjin, Tianjin, China; 11. Department of Head and Neck Oncology, Cancer Institute & Hospital, Tianjin Medical University, National Clinical Research Center for Cancer, Tianjin, Tianjin, China; 12. Department of Equipment and Materials, Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China展开收起
190
天
Redirecting expanded effector lymphocytes with engineered HER2 antibodies extends therapeutic sensitivity in HER2-non-amplified and trastuzumab-refractory breast cancer
作者
Hieu Trong Ngo; Elisa Cappuzzello; Pierangela Palmerini; Emilia Vigolo; Giulia D’Accardio; Lorenzo Nicolè; Gaia Griguolo; Valentina Guarneri; Steffen Krohn; Matthias Peipp; Antonio Rosato; Roberta Sommaggio展开收起
作者单位
1. Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; 2. Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy; 3. Department of Pathology, Angelo’s Hospital, Venice, Italy; 4. Medical Oncology 2, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy; 5. Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, University Hospital Schleswig-Holstein and Christian-Albrechts- University Kiel, Kiel, Germany展开收起
221
天
GLOBO H targeting CAR T Cells: generation and preclinical activity in gastrointestinal cancer cell lines
作者
Francesca Putti; Marco Gentili; Luca Roz; Elena Luison; Davide Tresoldi; Paolo Cappella; Marco Barella; Chiara C. Volpi; Licia Rivoltini; Giancarlo Pruneri; Filippo de Braud; Mariangela Figini; Francesca De Santis; Massimo Di Nicola展开收起
作者单位
1. Unit of Immunotherapy and Anticancer Innovative Therapeutics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 2. Epigenomics and biomarkers of solid tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; 3. ANP, Department of Advanced Diagnostics, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy; 4. Unit of Immunotherapy of Human Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 5. Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 6. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy展开收起
130
天
NAT10-mediated acetylation of JunB drives melanoma progression by enforcing SLC27A1-dependent lipid metabolic reprogramming
作者
Jianlan Liu; Bo Wang; Yurong Liu; Baogen Du; Xiaolong Cheng; Pengpeng Zhang; Xiaojian Cao; Shouyu Wang; Jian Tang展开收起
作者单位
1. Department of Hepatobiliary Surgery,The First Affiliated Hospital of Anhui Medical University; MOE Innovation Center for Basic Research in Tumor Immunotherapy; Anhui Province KeyLaboratory of Tumor Immune Microenvironment and Immunotherapy, Hefei, China; 2. Department of Plastic and Burns Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; 3. Department of Neurology, The Third Affiliated Hospital of Anhui Medical University, The First People’s Hospital of Hefei, Hefei, China; 4. Department of Lung Cancer, Tianjin Lung Cancer Center, Key Laboratory of Cancer Preventionand Therapy, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center forCancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; 5. Department of Orthopedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China展开收起
187
天
Development of gemcitabine-modified miR-15a as a novel, multimodal treatment strategy to overcome 5-FU and oxaliplatin resistance in colorectal cancer
作者
Anushka Ojha; Amartya Pal; Max Chao; Ramana V Davuluri; Jingfang Ju展开收起
作者单位
1. Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, USA; 2. Graduate Program in Molecular and Cellular Biology, Stony Brook University, Stony Brook, USA; 3. Department of Biomedical Informatics, Stony Brook Cancer Centre, Stony Brook University, Stony Brook, USA; 4. The Northport Veteran’s Administration Medical Center, Northport, USA展开收起
213
天
ERG inhibition selectively sensitizes ERG-positive prostate cancer to radiation through DNA repair vulnerabilities and enhances response to androgen receptor inhibitors
作者
Ayham Moustafa; Mohamed E. Elsesy; Bente Siebels; Jan Hahn; Su-Jung Oh-Hohenhorst; Carlotta Schudy; Thorsten Rieckmann; Susanne Burdak-Rothkamm; Derya Tilki; Tobias Maurer; Cordula Petersen; Kai Rothkamm; Gunhild von Amsberg; Carsten Bokemeyer; Hartmut Schlüter; Sabrina Köcher; Wael Y. Mansour展开收起
作者单位
1. Department of Radiotherapy and Radiooncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2. Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 3. Section of Mass Spectrometric Proteomics, University Medical Center Hamburg Eppendorf, Hamburg, Germany; 4. Pharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt; 5. Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 6. Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 7. Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK; 8. Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; 9. Department of Urology, Koc University Hospital, Istanbul, Türkiye; 10. Department of Oncology, II Med. Klinik, Hematology, BMT With Section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany展开收起
FAQ
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH审稿要多久?
截至2026-11-18,CrushSCI 收录了 JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 的 24 篇完整审稿记录。最快一篇从收稿到录用用了 11 天(Transcriptional evidence of neuroendocrine cell plasticity beyond histological boundaries in lung neuroendocrine neoplasms: an in-silico analysis suggesting a progression model,2026-07-08 收稿,2026-07-19 录用),最慢一篇用了 221 天;平均 139.4 天,中位数 142.5 天。
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
